Source : https://pubmed.ncbi.nlm.nih.gov/39331324/
TSA analysis revealed sufficient data exist to confirm ExTr will improve all five lipid outcomes. CT is optimal for lipid management. The modest effect observed may moderate dyslipidemia medication for...
Exercise training modestly improves five key lipid markers, with combined training (aerobic + resistance) being most effective. Sufficient data confirm benefits, though responses vary, potentially influencing dyslipidemia management strategies.
I generally discuss the LDL goals for all pts with DM and prior MI and adjust the medications aggressively myself
In a phase 2b study, efruxifermin added to stable GLP-1RA therapy in MASH patients with T2D was safe and reduced hepatic fat fraction by 65% vs. 10% with GLP-1RA alone. It also improved noninvasive fibrosis and metabolic markers without impacting weight loss benefits.
Did you know? Statins are linked to a 9–12% increased risk of new-onset diabetes, particularly with long-term, high-dose use and in patients with impaired glucose regulation. Still, their cardiovascular benefits usually outweigh this risk, prompting continued use in most at-risk populations.
Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?
Could statins’ effects on insulin release and sensitivity explain their role in glucose abnormalities?
